New drug cocktail aims to tame tough leukemias

NCT ID NCT07604233

Not yet recruiting Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of seven drugs (including asciminib and venetoclax) in 30 adults with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute myeloid leukemia. The first phase checks safety, and the second phase sees if the combo helps control the disease. Participants receive the drugs intravenously, by injection, or orally.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fludarabine, cytarabine, idarubicin, filgrastim, venetoclax, asciminib, blinatumomab
What this could lead to: If successful, this could offer a more effective treatment option for patients with advanced phases of chronic myeloid leukemia and Philadelphia chromosome-positive acute myeloid leukemia.
What could go wrong: This is an early-phase trial with only 30 participants, so results may not apply to everyone. The combination of multiple drugs may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA IN MYELOID BLAST PHASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia with BCR-ABL1 blast phase chronic myelogenous leukemia, BCR-ABL1 positive myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOID LEUKEMIA

Contacts and locations

Locations

UT MD Anderson

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.